Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Eroxon (MED3000)

Eroxon / MED3000 Topical Erectile Dysfunction Gel

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
FDA De Novo authorization / OTC clearance (June 2023)

Reference only. Not medical advice.

What can go wrong

The most common adverse events in trials were headache and application-site sensations, reported in only roughly 1-3% of men, so the safety profile is favorable. The main honest caveat is efficacy: it is intended for milder ED and its onset/response rates, while statistically significant, are lower and more modest than oral PDE5 inhibitors. It is not a substitute for medical evaluation of the cause of ED.

This is something to take to a clinician. The Atlas can tell you what is known about eroxon (med3000) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Eroxon (developed as MED3000 by Futura Medical) is a topical gel applied to the glans that received FDA de novo authorization in June 2023 as the first over-the-counter treatment for erectile dysfunction. It is regulated as a medical device rather than a drug because its makers describe a physical, non-medicated mechanism: volatile solvents evaporate on contact, producing a cooling-then-warming sensation that stimulates nerve endings and, per the manufacturer, triggers nitric oxide release and increased blood flow.

The first OTC erectile-dysfunction gel, classed as a device, not a drug.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Mild to moderate erectile dysfunction
  • On-demand use before intercourse
  • Men who prefer a non-oral, non-prescription option

How it is supposed to work

Futura Medical describes a physical rather than pharmacological action: volatile solvents in the gel evaporate rapidly on the sensitive glans, creating a cooling then warming stimulus of nerve endings that the company says promotes local nitric oxide release, smooth-muscle relaxation, and increased penile blood flow. This non-medicated framing is the basis for its device (not drug) classification.

What people get wrong

  • Often saidAn OTC gel works as reliably as Viagra

    ActuallyTrial data show statistically significant benefit for milder ED, but response rates are lower and more variable than oral PDE5 inhibitors; Eroxon is positioned as a first-line convenience option, not an equivalent to prescription therapy.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

Eroxon's appeal is speed (often under 10 minutes), OTC access, and a benign side-effect profile without systemic drug exposure or nitrate interaction. The trade-off is a more modest and variable effect than prescription PDE5 inhibitors, and the device-classification mechanism, while accepted by the FDA de novo pathway, rests largely on the manufacturer's physical-action model.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Sold over the counter in single-use tubes; positioned as an affordable, prescription-free on-demand option.

At a glance

Class
Topical gel, regulated as a device
FDA
De novo / OTC clearance, June 2023
Developer
Futura Medical
Onset (trials)
Erection in <10 min for ~45-60% of men

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Eroxon (MED3000). A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Futura FM57 and FM71 Phase 3 trialsreported

    ~60.1% (FM57) and ~44.9% (FM71) achieved erection in <10 minutes

  • IIEF-EF change at 24 weeksreported

    ~5.73-point improvement vs baseline, exceeding the FDA-agreed ~4-point minimal clinically important difference